Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial

Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet (British edition) Ročník 375; číslo 9717; s. 824 - 833
Hlavní autori:	Lingappa, Jairam R, Baeten, Jared M, Wald, Anna, Hughes, James P, Thomas, Katherine K, Mujugira, Andrew, Mugo, Nelly, Bukusi, Elizabeth A, Cohen, Craig R, Katabira, Elly, Ronald, Allan, Kiarie, James, Farquhar, Carey, Stewart, Grace John, Makhema, Joseph, Essex, Myron, Were, Edwin, Fife, Kenneth H, de Bruyn, Guy, Gray, Glenda E, McIntyre, James A, Manongi, Rachel, Kapiga, Saidi, Coetzee, David, Allen, Susan, Inambao, Mubiana, Kayitenkore, Kayitesi, Karita, Etienne, Kanweka, William, Delany, Sinead, Rees, Helen, Vwalika, Bellington, Magaret, Amalia S, Wang, Richard S, Kidoguchi, Lara, Barnes, Linda, Ridzon, Renee, Corey, Lawrence, Celum, Connie
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Kidlington Elsevier Ltd 06.03.2010 Elsevier Elsevier Limited
Predmet:	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral agents Antiviral agents Biological and medical sciences Disease transmission General aspects Herpes viruses Herpesvirus HIV Human immunodeficiency virus Human subjects Human viral diseases Infectious diseases Internal Medicine Medical sciences Mortality Pharmacology. Drug treatments Plasma Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Africa Acyclic nucleoside Purine nucleoside Prognosis HIV-1 virus Alphaherpesvirinae Daily Aciclovir Human herpesvirus 2 Nucleoside analog Antiviral Clinical trial Evolution DNA polymerase inhibitor Immunopathology Herpesviridae Retroviridae AIDS Immune deficiency Lentivirus Randomized controlled trial Infection Virus Medicine Viral disease Placebo Human immunodeficiency virus
ISSN:	0140-6736, 1474-547X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to aciclovir 400 mg orally twice daily or placebo, and were followed up for up to 24 months. Eligible participants had CD4 cell counts of 250 cells per μL or higher and were not taking antiretroviral therapy. We used block randomisation, and patients and investigators were masked to treatment allocation. Effect of aciclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per μL, antiretroviral therapy initiation, or non-trauma related death. As an exploratory analysis, we assessed the endpoint of CD4 falling to <350 cells per μL. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00194519. At enrolment, the median CD4 cell count was 462 cells per μL and median HIV-1 plasma RNA was 4·1 log 10 copies per μL. Aciclovir reduced risk of HIV-1 disease progression by 16%; 284 participants assigned aciclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0·84, 95% CI 0·71–0·98, p=0·03). In those with CD4 counts ≥350 cells per μL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per μL by 19% (0·81, 0·71–0·93, p=0·002) The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration. Bill & Melinda Gates Foundation.
AbstractList	Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to aciclovir 400 mg orally twice daily or placebo, and were followed up for up to 24 months. Eligible participants had CD4 cell counts of 250 cells per µL or higher and were not taking antiretroviral therapy. We used block randomisation, and patients and investigators were masked to treatment allocation. Effect of aciclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per µL, antiretroviral therapy initiation, or nontrauma related death. As an exploratory analysis, we assessed the endpoint of CD4 falling to <350 cells per µL. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00194519. At enrolment, the median CD4 cell count was 462 cells per µL and median HIV-1 plasma RNA was 4.1 log^sub 10^ copies per µL. Aciclovir reduced risk of HIV-1 disease progression by 16%; 284 participants assigned aciclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0.84, 95% CI 0.71-0.98, p=0.03). In those with CD4 counts ≥350 cells per µL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per µL by 19% (0.81, 0.71-0.93, p=0.002). The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration. Bill & Melinda Gates Foundation. Summary Background Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. Methods In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to aciclovir 400 mg orally twice daily or placebo, and were followed up for up to 24 months. Eligible participants had CD4 cell counts of 250 cells per μL or higher and were not taking antiretroviral therapy. We used block randomisation, and patients and investigators were masked to treatment allocation. Effect of aciclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per μL, antiretroviral therapy initiation, or non-trauma related death. As an exploratory analysis, we assessed the endpoint of CD4 falling to <350 cells per μL. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov , number NCT00194519. Findings At enrolment, the median CD4 cell count was 462 cells per μL and median HIV-1 plasma RNA was 4·1 log10 copies per μL. Aciclovir reduced risk of HIV-1 disease progression by 16%; 284 participants assigned aciclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0·84, 95% CI 0·71–0·98, p=0·03). In those with CD4 counts ≥350 cells per μL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per μL by 19% (0·81, 0·71–0·93, p=0·002) Interpretation The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration. Funding Bill & Melinda Gates Foundation. Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. Methods - In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to aciclovir 400 mg orally twice daily or placebo, and were followed up for up to 24 months. Eligible participants had CD4 cell counts of 250 cells per kL or higher and were not taking antiretroviral therapy. We used block randomisation, and patients and investigators were masked to treatment allocation. Effect of aciclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per kL, antiretroviral therapy initiation, or non-trauma related death. As an exploratory analysis, we assessed the endpoint of CD4 falling to <350 cells per kL. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00194519. Findings - At enrolment, the median CD4 cell count was 462 cells per kL and median HIV-1 plasmaA was 4 super(.1) log sub(10) copies per kL. Aciclovir reduced risk of HIV-1 disease progression by 16%; 284 participants assigned aciclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0 super(.84, 95% CI) 0 super(.71-0.98), p=0 super(.03)). In those with CD4 counts >=350 cells per kL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per kL by 19% (0 super(.81, 0.71-0.93), p=0 super(.002)) Interpretation - The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration. Funding - Bill & Melinda Gates Foundation. Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with 14 sites in southern Africa and east Africa, 3381 heterosexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assigned in a 1:1 ratio to aciclovir 400 mg orally twice daily or placebo, and were followed up for up to 24 months. Eligible participants had CD4 cell counts of 250 cells per μL or higher and were not taking antiretroviral therapy. We used block randomisation, and patients and investigators were masked to treatment allocation. Effect of aciclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per μL, antiretroviral therapy initiation, or non-trauma related death. As an exploratory analysis, we assessed the endpoint of CD4 falling to <350 cells per μL. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00194519. At enrolment, the median CD4 cell count was 462 cells per μL and median HIV-1 plasma RNA was 4·1 log 10 copies per μL. Aciclovir reduced risk of HIV-1 disease progression by 16%; 284 participants assigned aciclovir versus 324 assigned placebo reached the primary endpoint (hazard ratio [HR] 0·84, 95% CI 0·71–0·98, p=0·03). In those with CD4 counts ≥350 cells per μL, aciclovir delayed risk of CD4 cell counts falling to <350 cells per μL by 19% (0·81, 0·71–0·93, p=0·002) The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration. Bill & Melinda Gates Foundation.
Author	Magaret, Amalia S Coetzee, David Kapiga, Saidi Lingappa, Jairam R Allen, Susan Inambao, Mubiana Mujugira, Andrew McIntyre, James A Karita, Etienne Katabira, Elly Delany, Sinead Makhema, Joseph Gray, Glenda E Wald, Anna Kanweka, William Vwalika, Bellington Kidoguchi, Lara Corey, Lawrence Wang, Richard S Cohen, Craig R Were, Edwin Barnes, Linda Ridzon, Renee Manongi, Rachel Thomas, Katherine K de Bruyn, Guy Ronald, Allan Kayitenkore, Kayitesi Farquhar, Carey Celum, Connie Essex, Myron Mugo, Nelly Kiarie, James Stewart, Grace John Rees, Helen Fife, Kenneth H Bukusi, Elizabeth A Baeten, Jared M Hughes, James P
Author_xml	– sequence: 1 givenname: Jairam R surname: Lingappa fullname: Lingappa, Jairam R email: lingappa@u.washington.edu organization: Department of Global Health, Seattle, WA, USA – sequence: 2 givenname: Jared M surname: Baeten fullname: Baeten, Jared M organization: Department of Global Health, Seattle, WA, USA – sequence: 3 givenname: Anna surname: Wald fullname: Wald, Anna organization: Department of Medicine, Seattle, WA, USA – sequence: 4 givenname: James P surname: Hughes fullname: Hughes, James P organization: Department of Biostatistics, Seattle, WA, USA – sequence: 5 givenname: Katherine K surname: Thomas fullname: Thomas, Katherine K organization: Department of Medicine, Seattle, WA, USA – sequence: 6 givenname: Andrew surname: Mujugira fullname: Mujugira, Andrew organization: Department of Global Health, Seattle, WA, USA – sequence: 7 givenname: Nelly surname: Mugo fullname: Mugo, Nelly organization: Department of Global Health, Seattle, WA, USA – sequence: 8 givenname: Elizabeth A surname: Bukusi fullname: Bukusi, Elizabeth A organization: Department of Global Health, Seattle, WA, USA – sequence: 9 givenname: Craig R surname: Cohen fullname: Cohen, Craig R organization: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA – sequence: 10 givenname: Elly surname: Katabira fullname: Katabira, Elly organization: Infectious Disease Institute, Makerere University, Kampala, Uganda – sequence: 11 givenname: Allan surname: Ronald fullname: Ronald, Allan organization: Department of Medicine, University of Manitoba, Winnipeg, MB, Canada – sequence: 12 givenname: James surname: Kiarie fullname: Kiarie, James organization: Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya – sequence: 13 givenname: Carey surname: Farquhar fullname: Farquhar, Carey organization: Department of Medicine, Seattle, WA, USA – sequence: 14 givenname: Grace John surname: Stewart fullname: Stewart, Grace John organization: Department of Medicine, Seattle, WA, USA – sequence: 15 givenname: Joseph surname: Makhema fullname: Makhema, Joseph organization: Botswana-Harvard Partnership, Gabarone, Botswana – sequence: 16 givenname: Myron surname: Essex fullname: Essex, Myron organization: Department of Immunology and Infectious Diseases, Harvard University, Cambridge, MA, USA – sequence: 17 givenname: Edwin surname: Were fullname: Were, Edwin organization: Department of Reproductive Health, Moi University, Eldoret, Kenya – sequence: 18 givenname: Kenneth H surname: Fife fullname: Fife, Kenneth H organization: Department of Medicine, Indiana University, Indianopolis, IN, USA – sequence: 19 givenname: Guy surname: de Bruyn fullname: de Bruyn, Guy organization: Perinatal HIV Research Unit, Johannesburg, South Africa – sequence: 20 givenname: Glenda E surname: Gray fullname: Gray, Glenda E organization: Perinatal HIV Research Unit, Johannesburg, South Africa – sequence: 21 givenname: James A surname: McIntyre fullname: McIntyre, James A organization: Perinatal HIV Research Unit, Johannesburg, South Africa – sequence: 22 givenname: Rachel surname: Manongi fullname: Manongi, Rachel organization: Kilimanjaro Christian Medical Centre, Moshi, Tanzania – sequence: 23 givenname: Saidi surname: Kapiga fullname: Kapiga, Saidi organization: Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK – sequence: 24 givenname: David surname: Coetzee fullname: Coetzee, David organization: Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town, South Africa – sequence: 25 givenname: Susan surname: Allen fullname: Allen, Susan organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 26 givenname: Mubiana surname: Inambao fullname: Inambao, Mubiana organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 27 givenname: Kayitesi surname: Kayitenkore fullname: Kayitenkore, Kayitesi organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 28 givenname: Etienne surname: Karita fullname: Karita, Etienne organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 29 givenname: William surname: Kanweka fullname: Kanweka, William organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 30 givenname: Sinead surname: Delany fullname: Delany, Sinead organization: Reproductive Health and HIV Research Unit University of the Witwatersrand, Johannesburg, South Africa – sequence: 31 givenname: Helen surname: Rees fullname: Rees, Helen organization: Reproductive Health and HIV Research Unit University of the Witwatersrand, Johannesburg, South Africa – sequence: 32 givenname: Bellington surname: Vwalika fullname: Vwalika, Bellington organization: School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA – sequence: 33 givenname: Amalia S surname: Magaret fullname: Magaret, Amalia S organization: Department of Laboratory Medicine University of Washington, Seattle, WA, USA – sequence: 34 givenname: Richard S surname: Wang fullname: Wang, Richard S organization: Department of Global Health, Seattle, WA, USA – sequence: 35 givenname: Lara surname: Kidoguchi fullname: Kidoguchi, Lara organization: Department of Global Health, Seattle, WA, USA – sequence: 36 givenname: Linda surname: Barnes fullname: Barnes, Linda organization: Department of Global Health, Seattle, WA, USA – sequence: 37 givenname: Renee surname: Ridzon fullname: Ridzon, Renee organization: Bill & Melinda Gates Foundation, Seattle, WA, USA – sequence: 38 givenname: Lawrence surname: Corey fullname: Corey, Lawrence organization: Department of Medicine, Seattle, WA, USA – sequence: 39 givenname: Connie surname: Celum fullname: Celum, Connie organization: Department of Global Health, Seattle, WA, USA
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22504256$$DView record in Pascal Francis
BookMark	eNqNkV2L1DAUhous4OzqTxCCIOpF9SRN09ZFRdaPXVjwwg-8C5nk1M2aSWrSrs5P8d-azgwrDMh600J53qfnnPewOPDBY1Hcp_CUAhXPPgLlUIqmEo-heyIYVG3Z3SoWlDe8rHnz9aBYXCN3isOULgGAC6gXxe83yro1UdpqF65sJH2I5PTsS0mJsQlVQjLE8C1iSjZ4Yj0ZMAwOiZmUy0Hre9QjGvLTjhe7oPKGXGAcMJFkVxn-RbJ5SmRcD0jYc6JIzExY5R8YMjilcRlKHfwYg3P50xitcneL271yCe_t3kfF53dvP52clucf3p-dvD4vdV3zsWxgKWrsmeBAkdG8lDBGtZQZxnUremawUkuOCNBo2gJX1bJRDPMDoG1YdVQ82nrznj8mTKPMc2l0TnkMU5IN56LtqJjJB3vkZZiiz8NJ2nVQd03XZejhDlJJK9fnTbVNcoh2peJaMlYDZ7XIXL3ldAwpReyvEQpyrlVuapVzZxI6ualVzv7jvZy2oxrtfL1c5Y3pV9s05oteWYwyaYteo7Ex9yhNsDcaXu4ZtLPe5lW_4xrT34vIxCRsJbMDuo1hFrz4t-A_BvgDYtrmgA
CODEN	LANCAO
CitedBy_id	crossref_primary_10_1038_srep44084 crossref_primary_10_1016_S0140_6736_10_61069_0 crossref_primary_10_1016_j_jiac_2021_07_015 crossref_primary_10_1136_sextrans_2014_051867 crossref_primary_10_1002_jia2_25355 crossref_primary_10_1093_infdis_jiv318 crossref_primary_10_1089_vim_2015_0012 crossref_primary_10_1089_aid_2012_0206 crossref_primary_10_1097_QAD_0b013e328347fa37 crossref_primary_10_1007_s11904_017_0350_3 crossref_primary_10_1016_j_drugalcdep_2013_03_013 crossref_primary_10_1097_01_aids_0000390704_35642_47 crossref_primary_10_1371_journal_pone_0140765 crossref_primary_10_1371_journal_pone_0034635 crossref_primary_10_1007_s11904_011_0076_6 crossref_primary_10_1371_journal_pmed_1003938 crossref_primary_10_3390_biology13121050 crossref_primary_10_1097_QAD_0000000000001542 crossref_primary_10_1016_j_contraception_2016_12_003 crossref_primary_10_1177_0956462414543122 crossref_primary_10_1186_1471_2334_13_502 crossref_primary_10_1093_infdis_jir649 crossref_primary_10_1111_j_1600_0897_2010_00931_x crossref_primary_10_1371_journal_pone_0114989 crossref_primary_10_1016_S0140_6736_10_60705_2 crossref_primary_10_1093_cid_cir695 crossref_primary_10_1371_journal_pmed_1001251 crossref_primary_10_1016_j_clp_2010_08_012 crossref_primary_10_1097_QAD_0000000000001828 crossref_primary_10_1093_infdis_jir260 crossref_primary_10_1093_infdis_jir653 crossref_primary_10_1097_QAI_0b013e3182928eea crossref_primary_10_1097_COH_0b013e32833acafa crossref_primary_10_1128_CMR_00043_15 crossref_primary_10_1371_journal_pmed_1001123 crossref_primary_10_1258_ijsa_2009_008477 crossref_primary_10_1371_journal_pone_0059037 crossref_primary_10_1093_ve_veab011 crossref_primary_10_1128_AAC_05986_11 crossref_primary_10_1016_j_epidem_2017_12_001 crossref_primary_10_1371_journal_pone_0038622 crossref_primary_10_1016_S1473_3099_12_70050_6 crossref_primary_10_1258_ijsa_2009_009296 crossref_primary_10_1371_journal_pone_0022601 crossref_primary_10_1097_OLQ_0b013e318239d7fd crossref_primary_10_1258_ijsa_2010_010278 crossref_primary_10_1093_cid_cit539 crossref_primary_10_1097_QAI_0b013e3181fbcb76 crossref_primary_10_1097_01_aids_0000390707_58512_5e crossref_primary_10_1136_sextrans_2017_053336 crossref_primary_10_1016_S1473_3099_12_70037_3 crossref_primary_10_1007_s11908_012_0241_0 crossref_primary_10_1136_bmjopen_2013_004210 crossref_primary_10_1093_infdis_jit333 crossref_primary_10_1016_j_idc_2011_02_007 crossref_primary_10_1111_j_1600_0897_2010_00967_x crossref_primary_10_1177_1756285612456234 crossref_primary_10_1186_1745_6215_11_113 crossref_primary_10_1097_QAI_0000000000001199 crossref_primary_10_1097_QAI_0b013e318224d0ad crossref_primary_10_1097_QAD_0b013e32835ad473 crossref_primary_10_1186_1471_2334_12_277 crossref_primary_10_1097_MAJ_0000000000000321 crossref_primary_10_1258_ijsa_2012_011356 crossref_primary_10_1016_S0140_6736_14_60974_0 crossref_primary_10_1371_journal_ppat_1002109 crossref_primary_10_1093_jac_dky433 crossref_primary_10_1097_QAD_0b013e3283491e3e crossref_primary_10_1089_aid_2012_0071 crossref_primary_10_1016_j_jcv_2014_08_012 crossref_primary_10_1371_journal_pone_0019947 crossref_primary_10_1093_infdis_jix029 crossref_primary_10_1097_QAI_0000000000000013 crossref_primary_10_1016_S0140_6736_10_60097_9 crossref_primary_10_1038_srep42824 crossref_primary_10_1093_infdis_jiv765 crossref_primary_10_1002_rmv_656 crossref_primary_10_1016_j_epidem_2010_08_003 crossref_primary_10_1097_OLQ_0b013e318214b6e1 crossref_primary_10_1371_journal_pntd_0007886 crossref_primary_10_1097_QAD_0b013e3283489d45 crossref_primary_10_1128_JCM_01263_10 crossref_primary_10_1016_j_idc_2023_02_011 crossref_primary_10_1093_infdis_jir060 crossref_primary_10_1016_S1473_3099_12_70207_4 crossref_primary_10_1177_0956462414546504 crossref_primary_10_1097_QAI_0000000000001339 crossref_primary_10_1097_QAI_0000000000000520 crossref_primary_10_2217_fvl_11_119 crossref_primary_10_1093_cid_civ172 crossref_primary_10_1097_QAD_0b013e32835ecba9 crossref_primary_10_1155_2013_176459 crossref_primary_10_3390_v14030538 crossref_primary_10_1093_cid_cit208 crossref_primary_10_1097_OLQ_0b013e31820b8bc8 crossref_primary_10_1097_OLQ_0b013e31821d4ceb crossref_primary_10_3389_fcimb_2024_1471411 crossref_primary_10_1093_infdis_jit252 crossref_primary_10_1128_JVI_06077_11 crossref_primary_10_3390_tropicalmed5030136 crossref_primary_10_1016_S0140_6736_14_60164_1 crossref_primary_10_1097_QAI_0000000000000511 crossref_primary_10_1097_QAI_0000000000000113 crossref_primary_10_1136_sextrans_2016_052838 crossref_primary_10_1089_aid_2014_0207 crossref_primary_10_1097_QAI_0b013e31827971ca crossref_primary_10_1016_j_contraception_2018_01_011 crossref_primary_10_1093_infdis_jir747 crossref_primary_10_1016_S0140_6736_10_61070_7 crossref_primary_10_1016_j_clindermatol_2013_08_013 crossref_primary_10_1097_COH_0b013e3283582c8b
Cites_doi	10.1126/science.272.5265.1167 10.1038/325067a0 10.1056/NEJMoa062607 10.1086/345771 10.1128/CVI.00453-07 10.1086/522523 10.1001/jama.280.1.61 10.1097/01.olq.0000175377.88358.f3 10.1016/j.chom.2008.07.008 10.1097/QAD.0b013e32830a502e 10.1074/jbc.C800188200 10.1097/QAD.0b013e32832aadf2 10.1517/14656566.7.6.665 10.1086/422755 10.1006/viro.2000.0667 10.1016/S0140-6736(06)69861-9 10.1097/QAD.0b013e32831db217 10.1097/00002030-200106150-00009 10.1016/S0140-6736(98)07399-1 10.1136/bmj.319.7223.1492 10.1016/S0140-6736(99)03465-0 10.1080/01621459.1977.10480613 10.2165/00003495-200767020-00001 10.1097/QAD.0b013e328012b896 10.1097/QAD.0b013e328312c756 10.1086/512682 10.1097/00126334-200306010-00001 10.1086/383049 10.1086/593214 10.1001/jama.300.5.555 10.1056/NEJM199610103351502 10.1016/S0140-6736(04)17225-5 10.1056/NEJMoa0904849 10.1086/424519 10.1128/JCM.42.4.1794-1796.2004 10.1371/journal.pone.0001411 10.1056/NEJM199610103351501 10.1097/QAI.0b013e3181831832 10.1093/biostatistics/kxi014 10.1086/517297 10.1086/515621 10.1086/503258 10.1371/journal.pone.0005272 10.1001/jama.1994.03520060037029 10.1056/NEJMoa040541
ContentType	Journal Article
Copyright	2010 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright Elsevier Limited Mar 6-Mar 12, 2010
Copyright_xml	– notice: 2010 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright Elsevier Limited Mar 6-Mar 12, 2010
CorporateAuthor	for the Partners in Prevention HSV/HIV Transmission Study Team
CorporateAuthor_xml	– name: for the Partners in Prevention HSV/HIV Transmission Study Team
DBID	AAYXX CITATION IQODW 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7U1
DOI	10.1016/S0140-6736(09)62038-9
DatabaseName	CrossRef Pascal-Francis ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Database eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial Risk Abstracts
DatabaseTitle	CrossRef ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) Risk Abstracts
DatabaseTitleList	ProQuest One Psychology Risk Abstracts
Database_xml	– sequence: 1 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-547X
EndPage	833
ExternalDocumentID	1981972381 22504256 10_1016_S0140_6736_09_62038_9 S0140673609620389 1_s2_0_S0140673609620389
GeographicLocations	Africa
GeographicLocations_xml	– name: Africa
GroupedDBID	--- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AAEDT AAEDW AAEJM AAFWJ AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ABWVN ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ADBBV ADCNI ADMUD ADNMO ADXHL ADZCM AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AGQPQ AHHHB AHMBA AHQJS AIGII AIIUN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKVCP AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EFKBS EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ Q~Q R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UKHRP UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 ~HD 3V. 88A AACTN AAYOK ABTAH ACRZS AFCTW AFKWA AJOXV ALIPV AMFUW M0L M41 PKN RIG SDF ABLVK ABYKQ AHPSJ AJBFU NHB XFK Y6R ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS IQODW 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7U1
ID	FETCH-LOGICAL-c554t-70b65ef26401e216056dda812d24c86f2de3ab4ee007c1804a3b7a2eb7a008723
IEDL.DBID	M7P
ISICitedReferencesCount	116
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000275682600032&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0140-6736
IngestDate	Tue Oct 07 09:19:29 EDT 2025 Sun Oct 26 08:25:56 EDT 2025 Mon Jul 21 09:14:29 EDT 2025 Sat Nov 29 04:00:11 EST 2025 Tue Nov 18 22:26:56 EST 2025 Fri Feb 23 02:30:09 EST 2024 Sun Feb 23 10:19:30 EST 2025 Tue Oct 14 19:34:51 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9717
Keywords	Acyclic nucleoside Purine nucleoside Prognosis HIV-1 virus Alphaherpesvirinae Daily Aciclovir Human herpesvirus 2 Nucleoside analog Antiviral Clinical trial Evolution DNA polymerase inhibitor Immunopathology Herpesviridae Retroviridae AIDS Immune deficiency Lentivirus Randomized controlled trial Infection Virus Medicine Viral disease Placebo Human immunodeficiency virus
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c554t-70b65ef26401e216056dda812d24c86f2de3ab4ee007c1804a3b7a2eb7a008723
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
OpenAccessLink	http://doi.org/10.1016/S0140-6736(09)62038-9
PQID	199059799
PQPubID	40246
PageCount	10
ParticipantIDs	proquest_miscellaneous_744689162 proquest_journals_199059799 pascalfrancis_primary_22504256 crossref_primary_10_1016_S0140_6736_09_62038_9 crossref_citationtrail_10_1016_S0140_6736_09_62038_9 elsevier_sciencedirect_doi_10_1016_S0140_6736_09_62038_9 elsevier_clinicalkeyesjournals_1_s2_0_S0140673609620389 elsevier_clinicalkey_doi_10_1016_S0140_6736_09_62038_9
PublicationCentury	2000
PublicationDate	2010-03-06
PublicationDateYYYYMMDD	2010-03-06
PublicationDate_xml	– month: 03 year: 2010 text: 2010-03-06 day: 06
PublicationDecade	2010
PublicationPlace	Kidlington
PublicationPlace_xml	– name: Kidlington – name: London
PublicationTitle	The Lancet (British edition)
PublicationYear	2010
Publisher	Elsevier Ltd Elsevier Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited
References	Vickerman, Devine, Meyer-Rath, Foss, Delany-Moretlwe, Mayaud (bib47) 2009 Weiss (bib2) 2004; 11 Corbell C, Stergachis A, Ndowa F, Ndase P, Barnes L, Celum C. Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African Countries. Efron (bib29) 1977; 72 Modjarrad, Chamot, Vermund (bib31) 2008; 22 Mosca, Bednarik, Raj (bib10) 1987; 325 Anglaret, Chene, Attia (bib41) 1999; 353 Hammer, Katzenstein, Hughes (bib25) 1996; 335 Mole, Ripich, Margolis, Holodniy (bib6) 1997; 176 Rebbapragada, Wachihi, Pettengell (bib11) 2007; 21 Golden, Ashley-Morrow, Swenson, Hogrefe, Handsfield, Wald (bib23) 2005; 32 Altman, Andersen (bib30) 1999; 319 McMahon, Siliciano, Lai (bib35) 2008; 283 Volberding, Lagakos, Grimes (bib33) 1994; 272 (bib1) 2008 Mermin, Lule, Ekwaru (bib43) 2004; 364 Posavad, Wald, Kuntz (bib3) 2004; 190 Mellors, Rinaldo, Gupta, White, Todd, Kingsley (bib13) 1996; 272 (in press). Baeten, Chohan, Lavreys (bib50) 2007; 195 Katzenstein, Hammer, Hughes (bib32) 1996; 335 Ioannidis, Collier, Cooper (bib39) 1998; 178 Fawzi, Msamanga, Spiegelman (bib44) 2004; 351 Delany, N Mlaba, Clayton (bib15) 2009; 23 Zuckerman, Lucchetti, Whittington (bib18) 2007; 196 Celum, Wald, Lingappa (bib19) 2010; 362 Wiktor, Sassan-Morokro, Grant (bib40) 1999; 353 MacArthur, Novak, Peng (bib26) 2006; 368 Lavreys, Baeten, Chohan (bib12) 2006; 42 Baeten, Strick, Lucchetti (bib14) 2008; 198 Lingappa, Lambdin, Bukusi (bib21) 2008; 3 Gupta, Wald, Krantz (bib36) 2004; 190 Devine, Meyer-Rath, Foss (bib48) 2009 Walson, Otieno, Mbuchi (bib45) 2008; 22 Hammer, Eron, Reiss (bib28) 2008; 300 Nagot, Ouedraogo, Foulongne (bib17) 2007; 356 Gamiel, Tobian, Laeyendecker (bib22) 2008; 15 Gilbert, Sun (bib27) 2005; 6 Lisco, Vanpouille, Tchesnokov (bib34) 2008; 4 Mbopi-Keou, Legoff, Gresenguet (bib5) 2003; 33 Dunne, Whitehead, Sternberg (bib16) 2008; 49 Badri, Ehrlich, Wood, Maartens (bib42) 2001; 15 Lingappa, Kahle, Mugo (bib20) 2009; 4 Schacker, Ryncarz, Goddard, Diem, Shaughnessy, Corey (bib7) 1998; 280 Schacker, Zeh, Hu, Shaughnessy, Corey (bib8) 2002; 186 Laeyendecker, Henson, Gray (bib24) 2004; 42 Moriuchi, Moriuchi, Williams, Straus (bib9) 2000; 278 Baeten, McClelland, Corey (bib4) 2004; 189 Lingappa, Celum (bib38) 2007; 67 Baggaley, Griffin, Chapman (bib46) 2009; 23 Gupta, Wald (bib37) 2006; 7 Hammer (10.1016/S0140-6736(09)62038-9_bib25) 1996; 335 Wiktor (10.1016/S0140-6736(09)62038-9_bib40) 1999; 353 Lisco (10.1016/S0140-6736(09)62038-9_bib34) 2008; 4 Mosca (10.1016/S0140-6736(09)62038-9_bib10) 1987; 325 Celum (10.1016/S0140-6736(09)62038-9_bib19) 2010; 362 Rebbapragada (10.1016/S0140-6736(09)62038-9_bib11) 2007; 21 10.1016/S0140-6736(09)62038-9_bib49 Nagot (10.1016/S0140-6736(09)62038-9_bib17) 2007; 356 Laeyendecker (10.1016/S0140-6736(09)62038-9_bib24) 2004; 42 Golden (10.1016/S0140-6736(09)62038-9_bib23) 2005; 32 Lingappa (10.1016/S0140-6736(09)62038-9_bib38) 2007; 67 Mole (10.1016/S0140-6736(09)62038-9_bib6) 1997; 176 Baggaley (10.1016/S0140-6736(09)62038-9_bib46) 2009; 23 Modjarrad (10.1016/S0140-6736(09)62038-9_bib31) 2008; 22 Volberding (10.1016/S0140-6736(09)62038-9_bib33) 1994; 272 Mermin (10.1016/S0140-6736(09)62038-9_bib43) 2004; 364 Fawzi (10.1016/S0140-6736(09)62038-9_bib44) 2004; 351 Posavad (10.1016/S0140-6736(09)62038-9_bib3) 2004; 190 Mbopi-Keou (10.1016/S0140-6736(09)62038-9_bib5) 2003; 33 Walson (10.1016/S0140-6736(09)62038-9_bib45) 2008; 22 Gilbert (10.1016/S0140-6736(09)62038-9_bib27) 2005; 6 Lavreys (10.1016/S0140-6736(09)62038-9_bib12) 2006; 42 Katzenstein (10.1016/S0140-6736(09)62038-9_bib32) 1996; 335 McMahon (10.1016/S0140-6736(09)62038-9_bib35) 2008; 283 Mellors (10.1016/S0140-6736(09)62038-9_bib13) 1996; 272 Gupta (10.1016/S0140-6736(09)62038-9_bib36) 2004; 190 Baeten (10.1016/S0140-6736(09)62038-9_bib50) 2007; 195 Vickerman (10.1016/S0140-6736(09)62038-9_bib47) 2009 Efron (10.1016/S0140-6736(09)62038-9_bib29) 1977; 72 Gupta (10.1016/S0140-6736(09)62038-9_bib37) 2006; 7 Delany (10.1016/S0140-6736(09)62038-9_bib15) 2009; 23 Baeten (10.1016/S0140-6736(09)62038-9_bib14) 2008; 198 Zuckerman (10.1016/S0140-6736(09)62038-9_bib18) 2007; 196 Gamiel (10.1016/S0140-6736(09)62038-9_bib22) 2008; 15 Moriuchi (10.1016/S0140-6736(09)62038-9_bib9) 2000; 278 Anglaret (10.1016/S0140-6736(09)62038-9_bib41) 1999; 353 MacArthur (10.1016/S0140-6736(09)62038-9_bib26) 2006; 368 Lingappa (10.1016/S0140-6736(09)62038-9_bib20) 2009; 4 Dunne (10.1016/S0140-6736(09)62038-9_bib16) 2008; 49 Schacker (10.1016/S0140-6736(09)62038-9_bib7) 1998; 280 Ioannidis (10.1016/S0140-6736(09)62038-9_bib39) 1998; 178 Lingappa (10.1016/S0140-6736(09)62038-9_bib21) 2008; 3 Badri (10.1016/S0140-6736(09)62038-9_bib42) 2001; 15 Altman (10.1016/S0140-6736(09)62038-9_bib30) 1999; 319 (10.1016/S0140-6736(09)62038-9_bib1) 2008 Baeten (10.1016/S0140-6736(09)62038-9_bib4) 2004; 189 Hammer (10.1016/S0140-6736(09)62038-9_bib28) 2008; 300 Schacker (10.1016/S0140-6736(09)62038-9_bib8) 2002; 186 Devine (10.1016/S0140-6736(09)62038-9_bib48) 2009 Weiss (10.1016/S0140-6736(09)62038-9_bib2) 2004; 11
References_xml	– volume: 178 start-page: 349 year: 1998 end-page: 359 ident: bib39 article-title: Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data publication-title: J Infect Dis – volume: 364 start-page: 1428 year: 2004 end-page: 1434 ident: bib43 article-title: Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and viral load in HIV infection in rural Uganda publication-title: Lancet – volume: 21 start-page: 589 year: 2007 end-page: 598 ident: bib11 article-title: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract publication-title: AIDS – volume: 353 start-page: 1469 year: 1999 end-page: 1475 ident: bib40 article-title: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial publication-title: Lancet – reference: (in press). – volume: 195 start-page: 1177 year: 2007 end-page: 1180 ident: bib50 article-title: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads publication-title: J Infect Dis – year: 2009 ident: bib47 publication-title: Modelling the cost-effectiveness of (HSV-2) suppressive therapy among dually HIV and HSV-2 infected women in Johannesburg, South Africa (Poster P4.148) – volume: 176 start-page: 766 year: 1997 end-page: 770 ident: bib6 article-title: The impact of active herpes simplex virus infection on human immunodeficiency virus load publication-title: J Infect Dis – volume: 335 start-page: 1081 year: 1996 end-page: 1090 ident: bib25 article-title: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team publication-title: N Engl J Med – volume: 319 start-page: 1492 year: 1999 end-page: 1495 ident: bib30 article-title: Calculating the number needed to treat for trials where the outcome is time to an event publication-title: BMJ – volume: 368 start-page: 2125 year: 2006 end-page: 2135 ident: bib26 article-title: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial publication-title: Lancet – volume: 15 start-page: 888 year: 2008 end-page: 890 ident: bib22 article-title: Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda publication-title: Clin Vaccine Immunol – volume: 300 start-page: 555 year: 2008 end-page: 570 ident: bib28 article-title: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel publication-title: JAMA – volume: 15 start-page: 1143 year: 2001 end-page: 1148 ident: bib42 article-title: Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations publication-title: AIDS – volume: 67 start-page: 155 year: 2007 end-page: 174 ident: bib38 article-title: Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection publication-title: Drugs – volume: 362 start-page: 427 year: 2010 end-page: 439 ident: bib19 article-title: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2 publication-title: N Engl J Med – volume: 49 start-page: 77 year: 2008 end-page: 83 ident: bib16 article-title: Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand publication-title: J Acquir Immune Defic Syndr – volume: 190 start-page: 693 year: 2004 end-page: 696 ident: bib3 article-title: Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy publication-title: J Infect Dis – volume: 356 start-page: 790 year: 2007 end-page: 799 ident: bib17 article-title: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus publication-title: N Engl J Med – volume: 198 start-page: 1804 year: 2008 end-page: 1808 ident: bib14 article-title: Herpes simplex virus (HSV)—suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial publication-title: J Infect Dis – volume: 196 start-page: 1500 year: 2007 end-page: 1508 ident: bib18 article-title: Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial publication-title: J Infect Dis – volume: 3 start-page: e1411 year: 2008 ident: bib21 article-title: Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial publication-title: PLoS One – volume: 272 start-page: 437 year: 1994 end-page: 442 ident: bib33 article-title: The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group publication-title: JAMA – year: 2009 ident: bib48 publication-title: Cost and cost effectiveness of herpes simplex virus-type 2 (HSV-2) and suppressive therapy in HIV-1 and HSV-2 infected women in Johannesburg, South Africa (Poster P4.152) – volume: 23 start-page: 461 year: 2009 end-page: 469 ident: bib15 article-title: Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa publication-title: AIDS – volume: 335 start-page: 1091 year: 1996 end-page: 1098 ident: bib32 article-title: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team publication-title: N Engl J Med – volume: 7 start-page: 665 year: 2006 end-page: 675 ident: bib37 article-title: Genital herpes: antiviral therapy for symptom relief and prevention of transmission publication-title: Expert Opin Pharmacother – volume: 11 start-page: 24 year: 2004 end-page: 35 ident: bib2 article-title: Epidemiology of herpes simplex virus type 2 infection in the developing world publication-title: Herpes – volume: 189 start-page: 1466 year: 2004 end-page: 1471 ident: bib4 article-title: Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial publication-title: J Infect Dis – volume: 278 start-page: 534 year: 2000 end-page: 540 ident: bib9 article-title: Herpes simplex virus infection induces replication of human immunodeficiency virus type 1 publication-title: Virology – volume: 42 start-page: 1794 year: 2004 end-page: 1796 ident: bib24 article-title: Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans publication-title: J Clin Microbiol – volume: 6 start-page: 374 year: 2005 end-page: 394 ident: bib27 article-title: Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation publication-title: Biostatistics – volume: 351 start-page: 23 year: 2004 end-page: 32 ident: bib44 article-title: A randomized trial of multivitamin supplements and HIV disease progression and mortality publication-title: N Engl J Med – year: 2008 ident: bib1 publication-title: 2008 Report on the global AIDS epidemic – volume: 186 start-page: 1718 year: 2002 end-page: 1725 ident: bib8 article-title: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression publication-title: J Infect Dis – volume: 4 start-page: 260 year: 2008 end-page: 270 ident: bib34 article-title: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues publication-title: Cell Host Microbe – volume: 22 start-page: 2179 year: 2008 end-page: 2185 ident: bib31 article-title: Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression publication-title: AIDS – volume: 23 start-page: 1005 year: 2009 end-page: 1013 ident: bib46 article-title: Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load publication-title: AIDS – volume: 72 start-page: 557 year: 1977 end-page: 565 ident: bib29 article-title: Efficiency of Cox's likelihood function for censored data publication-title: J Am Statist Assoc – volume: 32 start-page: 771 year: 2005 end-page: 777 ident: bib23 article-title: Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic publication-title: Sex Transm Dis – volume: 33 start-page: 121 year: 2003 end-page: 124 ident: bib5 article-title: Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women publication-title: J Acquir Immune Defic Syndr – volume: 272 start-page: 1167 year: 1996 end-page: 1170 ident: bib13 article-title: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma publication-title: Science – volume: 4 start-page: e5272 year: 2009 ident: bib20 article-title: Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study publication-title: PLoS One – volume: 280 start-page: 61 year: 1998 end-page: 66 ident: bib7 article-title: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men publication-title: JAMA – volume: 353 start-page: 1463 year: 1999 end-page: 1468 ident: bib41 article-title: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group publication-title: Lancet – volume: 190 start-page: 1374 year: 2004 end-page: 1381 ident: bib36 article-title: Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract publication-title: J Infect Dis – reference: Corbell C, Stergachis A, Ndowa F, Ndase P, Barnes L, Celum C. Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African Countries. – volume: 22 start-page: 1601 year: 2008 end-page: 1609 ident: bib45 article-title: Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial publication-title: AIDS – volume: 325 start-page: 67 year: 1987 end-page: 70 ident: bib10 article-title: Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus publication-title: Nature – volume: 283 start-page: 31289 year: 2008 end-page: 31293 ident: bib35 article-title: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation publication-title: J Biol Chem – volume: 42 start-page: 1333 year: 2006 end-page: 1339 ident: bib12 article-title: Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women publication-title: Clin Infect Dis – volume: 272 start-page: 1167 year: 1996 ident: 10.1016/S0140-6736(09)62038-9_bib13 article-title: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma publication-title: Science doi: 10.1126/science.272.5265.1167 – volume: 325 start-page: 67 year: 1987 ident: 10.1016/S0140-6736(09)62038-9_bib10 article-title: Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus publication-title: Nature doi: 10.1038/325067a0 – volume: 356 start-page: 790 year: 2007 ident: 10.1016/S0140-6736(09)62038-9_bib17 article-title: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus publication-title: N Engl J Med doi: 10.1056/NEJMoa062607 – volume: 186 start-page: 1718 year: 2002 ident: 10.1016/S0140-6736(09)62038-9_bib8 article-title: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression publication-title: J Infect Dis doi: 10.1086/345771 – ident: 10.1016/S0140-6736(09)62038-9_bib49 – volume: 15 start-page: 888 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib22 article-title: Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00453-07 – volume: 196 start-page: 1500 year: 2007 ident: 10.1016/S0140-6736(09)62038-9_bib18 article-title: Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial publication-title: J Infect Dis doi: 10.1086/522523 – volume: 280 start-page: 61 year: 1998 ident: 10.1016/S0140-6736(09)62038-9_bib7 article-title: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men publication-title: JAMA doi: 10.1001/jama.280.1.61 – volume: 32 start-page: 771 year: 2005 ident: 10.1016/S0140-6736(09)62038-9_bib23 article-title: Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic publication-title: Sex Transm Dis doi: 10.1097/01.olq.0000175377.88358.f3 – year: 2009 ident: 10.1016/S0140-6736(09)62038-9_bib47 – year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib1 – volume: 4 start-page: 260 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib34 article-title: Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues publication-title: Cell Host Microbe doi: 10.1016/j.chom.2008.07.008 – volume: 22 start-page: 1601 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib45 article-title: Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial publication-title: AIDS doi: 10.1097/QAD.0b013e32830a502e – volume: 283 start-page: 31289 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib35 article-title: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation publication-title: J Biol Chem doi: 10.1074/jbc.C800188200 – volume: 23 start-page: 1005 year: 2009 ident: 10.1016/S0140-6736(09)62038-9_bib46 article-title: Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load publication-title: AIDS doi: 10.1097/QAD.0b013e32832aadf2 – volume: 7 start-page: 665 year: 2006 ident: 10.1016/S0140-6736(09)62038-9_bib37 article-title: Genital herpes: antiviral therapy for symptom relief and prevention of transmission publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.7.6.665 – volume: 190 start-page: 693 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib3 article-title: Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy publication-title: J Infect Dis doi: 10.1086/422755 – volume: 278 start-page: 534 year: 2000 ident: 10.1016/S0140-6736(09)62038-9_bib9 article-title: Herpes simplex virus infection induces replication of human immunodeficiency virus type 1 publication-title: Virology doi: 10.1006/viro.2000.0667 – volume: 368 start-page: 2125 year: 2006 ident: 10.1016/S0140-6736(09)62038-9_bib26 publication-title: Lancet doi: 10.1016/S0140-6736(06)69861-9 – volume: 11 start-page: 24 issue: suppl 1 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib2 article-title: Epidemiology of herpes simplex virus type 2 infection in the developing world publication-title: Herpes – volume: 23 start-page: 461 year: 2009 ident: 10.1016/S0140-6736(09)62038-9_bib15 article-title: Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa publication-title: AIDS doi: 10.1097/QAD.0b013e32831db217 – volume: 15 start-page: 1143 year: 2001 ident: 10.1016/S0140-6736(09)62038-9_bib42 article-title: Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations publication-title: AIDS doi: 10.1097/00002030-200106150-00009 – volume: 353 start-page: 1463 year: 1999 ident: 10.1016/S0140-6736(09)62038-9_bib41 article-title: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group publication-title: Lancet doi: 10.1016/S0140-6736(98)07399-1 – year: 2009 ident: 10.1016/S0140-6736(09)62038-9_bib48 – volume: 319 start-page: 1492 year: 1999 ident: 10.1016/S0140-6736(09)62038-9_bib30 article-title: Calculating the number needed to treat for trials where the outcome is time to an event publication-title: BMJ doi: 10.1136/bmj.319.7223.1492 – volume: 353 start-page: 1469 year: 1999 ident: 10.1016/S0140-6736(09)62038-9_bib40 article-title: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(99)03465-0 – volume: 72 start-page: 557 year: 1977 ident: 10.1016/S0140-6736(09)62038-9_bib29 article-title: Efficiency of Cox's likelihood function for censored data publication-title: J Am Statist Assoc doi: 10.1080/01621459.1977.10480613 – volume: 67 start-page: 155 year: 2007 ident: 10.1016/S0140-6736(09)62038-9_bib38 article-title: Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection publication-title: Drugs doi: 10.2165/00003495-200767020-00001 – volume: 21 start-page: 589 year: 2007 ident: 10.1016/S0140-6736(09)62038-9_bib11 article-title: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract publication-title: AIDS doi: 10.1097/QAD.0b013e328012b896 – volume: 22 start-page: 2179 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib31 article-title: Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression publication-title: AIDS doi: 10.1097/QAD.0b013e328312c756 – volume: 195 start-page: 1177 year: 2007 ident: 10.1016/S0140-6736(09)62038-9_bib50 article-title: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads publication-title: J Infect Dis doi: 10.1086/512682 – volume: 33 start-page: 121 year: 2003 ident: 10.1016/S0140-6736(09)62038-9_bib5 article-title: Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200306010-00001 – volume: 189 start-page: 1466 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib4 article-title: Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial publication-title: J Infect Dis doi: 10.1086/383049 – volume: 198 start-page: 1804 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib14 article-title: Herpes simplex virus (HSV)—suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial publication-title: J Infect Dis doi: 10.1086/593214 – volume: 300 start-page: 555 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib28 article-title: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel publication-title: JAMA doi: 10.1001/jama.300.5.555 – volume: 335 start-page: 1091 year: 1996 ident: 10.1016/S0140-6736(09)62038-9_bib32 article-title: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team publication-title: N Engl J Med doi: 10.1056/NEJM199610103351502 – volume: 364 start-page: 1428 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib43 article-title: Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and viral load in HIV infection in rural Uganda publication-title: Lancet doi: 10.1016/S0140-6736(04)17225-5 – volume: 362 start-page: 427 year: 2010 ident: 10.1016/S0140-6736(09)62038-9_bib19 article-title: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2 publication-title: N Engl J Med doi: 10.1056/NEJMoa0904849 – volume: 190 start-page: 1374 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib36 article-title: Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract publication-title: J Infect Dis doi: 10.1086/424519 – volume: 42 start-page: 1794 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib24 article-title: Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans publication-title: J Clin Microbiol doi: 10.1128/JCM.42.4.1794-1796.2004 – volume: 3 start-page: e1411 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib21 article-title: Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial publication-title: PLoS One doi: 10.1371/journal.pone.0001411 – volume: 335 start-page: 1081 year: 1996 ident: 10.1016/S0140-6736(09)62038-9_bib25 article-title: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team publication-title: N Engl J Med doi: 10.1056/NEJM199610103351501 – volume: 49 start-page: 77 year: 2008 ident: 10.1016/S0140-6736(09)62038-9_bib16 article-title: Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181831832 – volume: 6 start-page: 374 year: 2005 ident: 10.1016/S0140-6736(09)62038-9_bib27 article-title: Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation publication-title: Biostatistics doi: 10.1093/biostatistics/kxi014 – volume: 176 start-page: 766 year: 1997 ident: 10.1016/S0140-6736(09)62038-9_bib6 article-title: The impact of active herpes simplex virus infection on human immunodeficiency virus load publication-title: J Infect Dis doi: 10.1086/517297 – volume: 178 start-page: 349 year: 1998 ident: 10.1016/S0140-6736(09)62038-9_bib39 article-title: Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data publication-title: J Infect Dis doi: 10.1086/515621 – volume: 42 start-page: 1333 year: 2006 ident: 10.1016/S0140-6736(09)62038-9_bib12 article-title: Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women publication-title: Clin Infect Dis doi: 10.1086/503258 – volume: 4 start-page: e5272 year: 2009 ident: 10.1016/S0140-6736(09)62038-9_bib20 article-title: Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study publication-title: PLoS One doi: 10.1371/journal.pone.0005272 – volume: 272 start-page: 437 year: 1994 ident: 10.1016/S0140-6736(09)62038-9_bib33 article-title: The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group publication-title: JAMA doi: 10.1001/jama.1994.03520060037029 – volume: 351 start-page: 23 year: 2004 ident: 10.1016/S0140-6736(09)62038-9_bib44 article-title: A randomized trial of multivitamin supplements and HIV disease progression and mortality publication-title: N Engl J Med doi: 10.1056/NEJMoa040541
SSID	ssj0004605
Score	2.3736327
Snippet	Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1... Summary Background Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma...
SourceID	proquest pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	824
SubjectTerms	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral agents Antiviral agents Biological and medical sciences Disease transmission General aspects Herpes viruses Herpesvirus HIV Human immunodeficiency virus Human subjects Human viral diseases Infectious diseases Internal Medicine Medical sciences Mortality Pharmacology. Drug treatments Plasma Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Title	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0140673609620389 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673609620389 https://dx.doi.org/10.1016/S0140-6736(09)62038-9 https://www.proquest.com/docview/199059799 https://www.proquest.com/docview/744689162
Volume	375
WOSCitedRecordID	wos000275682600032&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: AUTh Library subscriptions: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELbYhhDSxG-0Mqj8wAM8hMWOE6e8IBibhkRLNUbVN8txHClSlZSmneBP4b_lznEyIQpD4uWkJPqSOL6cz77Pd4Q8N1yDm5-aIBJpEog8xvhuLAOZMV4UWkrmynTOPsrJJJ3PR1PPzWk8rbKzic5Q57XBNfIjBmYzxhjUm-XXAItGYXDVV9DYIXuYJCFyzL3ptm2RjuF-tYHn6HN_8kU4epnwEH_7Pw1N-0vdwAcr2koXvxltNxKd3v3PNtwjd7wLSt-2OnOf3LDVA3Jr7IPsD8mP97pcfKfawOX6slxR8Gvp2YdZwKgP51DH6mozetCyoi0NneK2LgC2_C6bU1zj9UBd5RS0Y2kb2pSYkPgbhTtvGopLwJS_pppCu_MatA6AjiiW1YHn0S_glKsu8oh8OT25OD4LfAWHwICbsg5kmCWxLcDpCpnlDPojyXMNPkXOhUmTguc20pmwFjwVw9JQ6CiTmlsQmCuPR4_JblVX9oBQo9MkLxjHAltCZCIV8CVjG2cGDDSLzICIrvOU8enNscrGQm3hsYUj5fpcjQbkVQ9btvk9rgMknWaobvMqmFsFI9B1QLkNaBtvNBrFVMNV2KIRDLNLhAIy7ZHeL2r9nX956PAX5e3byDF1Hbi7A3LYqaq6epFOTweE9ldBATCWpCtbbxolhUhSmFrwJ3-9wSG53dItsITIU7K7Xm3sM3LTXK7LZjUkO_J8hnIuQabHbEj23p1MpudwNA5beYGSj5385OR06H7zn8iGSvU
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgQAJcUeUwfADSPAQFrvOpUgIIcbUam2FRJn2ZhzbkSJVSanbwX4KP4L_yDlxkglRGC974CUPib40tc_N9nfOIeSp5grC_FQHfZHGgTARnu9GSZBkjOe5ShJWt-k8GifTaXp8PPiwRX60uTBIq2xtYm2oTaVxj3yPgdmM8AzqzeJLgE2j8HC17aDhpeLQnn6FFZt7PdqH6X3G-cH72bth0DQVCDR4zlWQhFkc2RzigJBZziCaj41R4OYMFzqNc25sX2XCWnCemqWhUP0sUdzCBcu3YZ0DsPiXsKweMggn4WxTGmbNqD9LGNr72N18Hg5exDxEM_MnV3h9oRxMUO47a_zmJGrPd3DzPxuzW-RGE2LTt14nbpMtW94hVyYNieAu-b6vivkpVRoeVyfFkkLcToejo4DR5riK1qw1X7GEFiX1NHuKaWsA9Pw1ayjuYTdAVRoK0r-wjroCCy5_o_DmtaO4xU35K6oojLOpQKsAWBPhsipo8gTmcKvunnKPfLqQgblPtsuqtA8I1SqNTc44NhATIhOpgJmLbJRpcECsr3tEtMIidVO-HbuIzOUGnl44kLWMyUGPvOxgC1-_5DxA3EqibJNzwZ1I8LDnAZNNQOsao-gkk47L0KMRDKtnhAIy7ZBN3OfjuX_50d1flKX7jxxL80E43yM7rWrIsw9p9aJHaPcUBADPylRpq7WTiRBxCksn_vCvL3hCrg5nk7Ecj6aHO-Sap5Zgu5RHZHu1XNvH5LI-WRVuuVubCko-X7Se_QQQq52Y
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgSYkxB3RDYYfQIKH0NhxLkVCCK1UqzaqScC0N-PYjhSpSrq6Heyn8FP4d5yTOJ0QhfGyB17ykOhLU_vcbH_nHEKeaa4gzM90EIksCYSJ8Xw3ToM0Z7woVJqypk3n8WE6mWQnJ4OjDfKjy4VBWmVnExtDbWqNe-R9BmYzxjOofuFZEUfD0dvZaYANpPCgteum0UrIgT3_Cqs392Y8hKl-zvno_ae9_cA3GAg0eNFFkIZ5EtsCYoKQWc4gsk-MUeDyDBc6SwpubKRyYS04Us2yUKgoTxW3cMFSbljzAKz_tTQCIcYk9T22LiWzYddfJA_1P65uvggHLxMeosn5k1u8OVMOJqtou2z85jAaLzi6_R-P3x1yy4fe9F2rK3fJhq3uka0Pnlxwn3wfqnJ6TpWGx_VZOacQz9P98XHAqD_Gog2bra1kQsuKtvR7iulsAGx5bdZQ3Nv2QFUZCloxs466Egsxf6Pw5qWjuPVN-WuqKIy5qUHbANgQ5PI68PkDU7jVdFV5QD5fycA8JJtVXdlHhGqVJaZgHBuLCZGLTMAsxjbONTgmFukeEZ3gSO3LumN3kalcw98LB7KRNznokVcr2Kyta3IZIOmkUnZJu-BmJHjey4DpOqB13lg6yaTjMmzRCIZVNUIBma2QPh5s47x_-dHdXxRn9R85luyDML9Hdjo1kRcf0ulIj9DVUxAAPENTla2XTqZCJBksqfj2X1_wlGyBesnD8eRgh9xoGSfYReUx2VzMl_YJua7PFqWb7zZWg5IvV61mPwHafqYW
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daily+aciclovir+for+HIV-1+disease+progression+in+people+dually+infected+with+HIV-1+and+herpes+simplex+virus+type+2%3A+a+randomised+placebo-controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Lingappa%2C+Jairam+R&rft.au=Baeten%2C+Jared+M&rft.au=Wald%2C+Anna&rft.au=Hughes%2C+James+P&rft.date=2010-03-06&rft.issn=0140-6736&rft.volume=375&rft.issue=9717&rft.spage=824&rft.epage=833&rft_id=info:doi/10.1016%2FS0140-6736%2809%2962038-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S0140_6736_09_62038_9
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673610X61165%2Fcov150h.gif